Meridian Bioscience (VIVO) Misses Q3 EPS by 1c

Meridian Bioscience (NASDAQ: VIVO) reported Q3 EPS of $0.16, $0.01 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $67.8 million versus the consensus estimate of $66.8 million.

For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.

You May Also Be Interested In

• Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
• ArcelorMittal Q2 2026 analyst consensus: $2.04B EBITDA expected
• Lockheed Martin (LMT) PT Raised to $581 at UBS on Revenue Growth Momentum